Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q2 2024 Earnings Conference Call August 15, 2024 8:00 AM ET
Company Participants
Alexander Lobo - Precision AQ, Investor Relations
Milton Werner - President and Chief Executive Officer
Garth Lees-Rolfe - Chief Financial Officer
Conference Call Participants
Jason McCarthy - Maxim Group
Edward White - H.C. Wainwright
Operator
Greetings and welcome to the Inhibikase Therapeutics Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Alex Lobo, Precision AQ, Investor Relations. Thank you, sir. You may begin.
Alexander Lobo
Good morning, and welcome to Inhibikase Therapeutics' Second Quarter 2024 Financial Results Conference Call and Audio Webcast. With me today is Dr. Milton Werner, Chief Executive Officer; and Garth Lees-Rolfe, Chief Financial Officer.
On August 14th, Inhibikase issued a press release announcing financial results for the second quarter ended June 30th, 2024. We encourage everyone to read yesterday's press release as well as Inhibikase's quarterly report on Form 10-Q, which has been filed with the SEC.
The company's press release and Form 10-Q are also available on Inhibikase's website at inhibikase.com. In addition, this conference call is being webcast through the Investor Relations section of the company's website and will be archived there for future reference.
Please note that certain information on today's call is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Participants are cautioned that this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, August 15th, 2024.
Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. Information on potential risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov.
The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this webcast, except as may be required by applicable securities law.
With that said, I would like to turn the call over to Dr. Milton Werner. Milton, you may begin.
Milton Werner
Thank you, Alex. Thank you everybody for joining us today to review our second quarter 2024 financial results and recent clinical and business updates.